[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645523":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":40,"centralContacts":50,"locations":58,"responsibleParty":340,"collaborators":28,"id":342,"slug":343,"hasResults":344,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":344,"sex":350,"minAge":351,"maxAge":28,"enrollmentInfo":352,"targetDuration":28,"studyType":355,"phases":356,"briefSummary":358,"conditions":359,"keywords":361,"overallStatus":369,"whyStopped":28,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":379},{"fullName":5,"class":6},"Akeso","INDUSTRY",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Cadonilimab\u002Fplacebo+CAPOX","EXPERIMENTAL","Cadonilimab\u002Fplacebo in combination with oxaliplatin and capecitabine (CAPOX)",[13,14,15],"Drug: Cadonilimab","Drug: CAPOX regimen","Drug: Placebo",{"label":17,"type":18,"description":19,"interventionNames":20},"CAPOX±nivolumab\u002Fplacebo","ACTIVE_COMPARATOR","Oxaliplatin and capecitabine with or without nivolumab (CAPOX)",[14,21,15],"Drug: Nivolumab",[23,29,33,37],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Cadonilimab","Anti-PD-1\u002F CTLA-4 tetrameric bispecific antibody",[9],null,{"type":24,"name":30,"description":31,"armGroupLabels":32,"otherNames":28},"CAPOX regimen","A combination treatment contains oxaliplatin and capecitabine",[17,9],{"type":24,"name":34,"description":35,"armGroupLabels":36,"otherNames":28},"Nivolumab","Anti-PD-1 monoclonal antibody",[17],{"type":24,"name":38,"description":38,"armGroupLabels":39,"otherNames":28},"Placebo",[17,9],[41,45,47],{"name":42,"affiliation":43,"role":44},"Jiafu Ji, MD","Peking University Cancer Hospital, Beijing, Beijing 100142, China","PRINCIPAL_INVESTIGATOR",{"name":46,"affiliation":43,"role":44},"Lin Shen, MD",{"name":48,"affiliation":49,"role":44},"Markus Mohler, MD","Johannes Gutenberg University Clinic, Germany",[51,56],{"name":52,"role":53,"phone":54,"phoneExt":28,"email":55},"Zhifang Yao, MD","CONTACT","86-0760-89873999","clinicaltrials@akesobio.com",{"name":57,"role":53,"phone":28,"phoneExt":28,"email":28},"Yelena Janjigian, MD",[59,75,88,101,114,124,137,149,155,168,181,191,203,216,229,236,243,254,265,279,290,300,308,318,329],{"facility":60,"status":28,"city":61,"state":62,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"Mayo Clinic","Phoenix","Arizona","85054","United States","US",{"type":67,"coordinates":68},"Point",[69,70],-112.07404,33.44838,{"lat":70,"lon":69},[73],{"name":74,"role":53,"phone":28,"phoneExt":28,"email":28},"Ashish Chintakuntlawar,",{"facility":76,"status":28,"city":77,"state":78,"zip":79,"country":64,"countryCode":65,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"UCLA Health","Los Angeles","California","90095",{"type":67,"coordinates":81},[82,83],-118.24368,34.05223,{"lat":83,"lon":82},[86],{"name":87,"role":53,"phone":28,"phoneExt":28,"email":28},"Randy Hecht, MD",{"facility":89,"status":28,"city":90,"state":91,"zip":92,"country":64,"countryCode":65,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Rocky Mountain Cancer Centers","Denver","Colorado","80218",{"type":67,"coordinates":94},[95,96],-104.9847,39.73915,{"lat":96,"lon":95},[99],{"name":100,"role":53,"phone":28,"phoneExt":28,"email":28},"Allen L Cohn, MD",{"facility":102,"status":28,"city":103,"state":104,"zip":105,"country":64,"countryCode":65,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Yale School of Medicine","New Haven","Connecticut","06510",{"type":67,"coordinates":107},[108,109],-72.92816,41.30815,{"lat":109,"lon":108},[112],{"name":113,"role":53,"phone":28,"phoneExt":28,"email":28},"Raghav Sundar, MD",{"facility":115,"status":28,"city":116,"state":117,"zip":118,"country":64,"countryCode":65,"cosmosGeoPoint":119,"geoPoint":123,"contacts":28},"Dana Farber Cancer Institute","Boston","Massachusetts","02215",{"type":67,"coordinates":120},[121,122],-71.05977,42.35843,{"lat":122,"lon":121},{"facility":125,"status":28,"city":126,"state":127,"zip":128,"country":64,"countryCode":65,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"Henry Ford Health","Detroit","Michigan","48202",{"type":67,"coordinates":130},[131,132],-83.04575,42.33143,{"lat":132,"lon":131},[135],{"name":136,"role":53,"phone":28,"phoneExt":28,"email":28},"Zaid AI-Saheli, MD",{"facility":138,"status":28,"city":139,"state":139,"zip":140,"country":64,"countryCode":65,"cosmosGeoPoint":141,"geoPoint":145,"contacts":146},"Mount Sinai","New York","10029",{"type":67,"coordinates":142},[143,144],-74.00597,40.71427,{"lat":144,"lon":143},[147],{"name":148,"role":53,"phone":28,"phoneExt":28,"email":28},"Deirdre Cohen, MD",{"facility":150,"status":28,"city":139,"state":139,"zip":151,"country":64,"countryCode":65,"cosmosGeoPoint":152,"geoPoint":154,"contacts":28},"Memorial Sloan Kettering Cancer Center","10065",{"type":67,"coordinates":153},[143,144],{"lat":144,"lon":143},{"facility":156,"status":28,"city":157,"state":158,"zip":159,"country":64,"countryCode":65,"cosmosGeoPoint":160,"geoPoint":164,"contacts":165},"Oregon Health and Science University","Portland","Oregon","97239",{"type":67,"coordinates":161},[162,163],-122.67621,45.52345,{"lat":163,"lon":162},[166],{"name":167,"role":53,"phone":28,"phoneExt":28,"email":28},"Emerson Chen, MD",{"facility":169,"status":28,"city":170,"state":171,"zip":172,"country":64,"countryCode":65,"cosmosGeoPoint":173,"geoPoint":177,"contacts":178},"Sarah Cannon Research Institute (SCRI) - Oncology Partners","Nashville","Tennessee","37203",{"type":67,"coordinates":174},[175,176],-86.78444,36.16589,{"lat":176,"lon":175},[179],{"name":180,"role":53,"phone":28,"phoneExt":28,"email":28},"David R Spigel, MD",{"facility":182,"status":28,"city":183,"state":184,"zip":185,"country":64,"countryCode":65,"cosmosGeoPoint":186,"geoPoint":190,"contacts":28},"Baylor Scott & White Health","Dallas","Texas","75246",{"type":67,"coordinates":187},[188,189],-96.80667,32.78306,{"lat":189,"lon":188},{"facility":192,"status":28,"city":193,"state":184,"zip":194,"country":64,"countryCode":65,"cosmosGeoPoint":195,"geoPoint":199,"contacts":200},"MD Anderson Cancer Center","Houston","77030",{"type":67,"coordinates":196},[197,198],-95.36327,29.76328,{"lat":198,"lon":197},[201],{"name":202,"role":53,"phone":28,"phoneExt":28,"email":28},"Jaffer A. Ajani,, MD",{"facility":204,"status":28,"city":205,"state":206,"zip":207,"country":64,"countryCode":65,"cosmosGeoPoint":208,"geoPoint":212,"contacts":213},"University of Wisconsin Carbone Cancer Center","Madison","Wisconsin","53792",{"type":67,"coordinates":209},[210,211],-89.40123,43.07305,{"lat":211,"lon":210},[214],{"name":215,"role":53,"phone":28,"phoneExt":28,"email":28},"Nataliya Uboha, MD",{"facility":217,"status":28,"city":218,"state":28,"zip":28,"country":219,"countryCode":220,"cosmosGeoPoint":221,"geoPoint":225,"contacts":226},"Beijing Friendship Hospital, Capital Medical University","Beijing","China","CN",{"type":67,"coordinates":222},[223,224],116.39723,39.9075,{"lat":224,"lon":223},[227],{"name":228,"role":53,"phone":28,"phoneExt":28,"email":28},"Wei Deng, MD",{"facility":230,"status":28,"city":218,"state":28,"zip":28,"country":219,"countryCode":220,"cosmosGeoPoint":231,"geoPoint":233,"contacts":234},"Peking University Cancer Hospital, Gastrointestinal Cancer Center I",{"type":67,"coordinates":232},[223,224],{"lat":224,"lon":223},[235],{"name":42,"role":53,"phone":28,"phoneExt":28,"email":28},{"facility":237,"status":28,"city":218,"state":28,"zip":28,"country":219,"countryCode":220,"cosmosGeoPoint":238,"geoPoint":240,"contacts":241},"Peking University Cancer Hospital, Gastrointestinal Oncology",{"type":67,"coordinates":239},[223,224],{"lat":224,"lon":223},[242],{"name":46,"role":53,"phone":28,"phoneExt":28,"email":28},{"facility":244,"status":28,"city":245,"state":28,"zip":28,"country":219,"countryCode":220,"cosmosGeoPoint":246,"geoPoint":250,"contacts":251},"Guangdong Provincial People's Hospital","Guangzhou",{"type":67,"coordinates":247},[248,249],113.25,23.11667,{"lat":249,"lon":248},[252],{"name":253,"role":53,"phone":28,"phoneExt":28,"email":28},"Jian Xiao, MD",{"facility":255,"status":28,"city":256,"state":28,"zip":28,"country":219,"countryCode":220,"cosmosGeoPoint":257,"geoPoint":261,"contacts":262},"Zhongshan Hospital Fudan University","Shanghai",{"type":67,"coordinates":258},[259,260],121.45806,31.22222,{"lat":260,"lon":259},[263],{"name":264,"role":53,"phone":28,"phoneExt":28,"email":28},"Xuefei Wang, MD",{"facility":266,"status":28,"city":267,"state":268,"zip":28,"country":269,"countryCode":270,"cosmosGeoPoint":271,"geoPoint":275,"contacts":276},"Universitaetsklinikum Essen","Essen","North Rhine-Westphalia","Germany","DE",{"type":67,"coordinates":272},[273,274],7.01228,51.45657,{"lat":274,"lon":273},[277],{"name":278,"role":53,"phone":28,"phoneExt":28,"email":28},"Isabel Virchow, MD",{"facility":280,"status":28,"city":281,"state":28,"zip":28,"country":269,"countryCode":270,"cosmosGeoPoint":282,"geoPoint":286,"contacts":287},"University Cancer Center Frankfurt","Frankfurt",{"type":67,"coordinates":283},[284,285],10.53333,49.68333,{"lat":285,"lon":284},[288],{"name":289,"role":53,"phone":28,"phoneExt":28,"email":28},"Thorsten O Goetze, MD",{"facility":291,"status":28,"city":292,"state":28,"zip":28,"country":269,"countryCode":270,"cosmosGeoPoint":293,"geoPoint":297,"contacts":298},"Universitätsmedizin der Johannes Gutenberg-Universität","Mainz",{"type":67,"coordinates":294},[295,296],8.28008,49.98185,{"lat":296,"lon":295},[299],{"name":48,"role":53,"phone":28,"phoneExt":28,"email":28},{"facility":301,"status":28,"city":302,"state":28,"zip":28,"country":269,"countryCode":270,"cosmosGeoPoint":303,"geoPoint":307,"contacts":28},"Univerity Marburg","Marburg",{"type":67,"coordinates":304},[305,306],8.77069,50.80904,{"lat":306,"lon":305},{"facility":309,"status":28,"city":310,"state":28,"zip":28,"country":311,"countryCode":312,"cosmosGeoPoint":313,"geoPoint":317,"contacts":28},"Pratia MCM Kraków","Krakow","Poland","PL",{"type":67,"coordinates":314},[315,316],19.93658,50.06143,{"lat":316,"lon":315},{"facility":319,"status":28,"city":320,"state":28,"zip":28,"country":311,"countryCode":312,"cosmosGeoPoint":321,"geoPoint":325,"contacts":326},"Pratia Poznań","Poznan",{"type":67,"coordinates":322},[323,324],16.92993,52.40692,{"lat":324,"lon":323},[327],{"name":328,"role":53,"phone":28,"phoneExt":28,"email":28},"Piotr Tomczak, MD",{"facility":330,"status":28,"city":331,"state":28,"zip":28,"country":311,"countryCode":312,"cosmosGeoPoint":332,"geoPoint":336,"contacts":337},"Narodowy Instytut Onkologii-im. Marii Sklodowskiej Curie Panstwowy Instytut Badawczy - w Warszawie","Warsaw",{"type":67,"coordinates":333},[334,335],21.01178,52.22977,{"lat":335,"lon":334},[338],{"name":339,"role":53,"phone":28,"phoneExt":28,"email":28},"Lucjan S Wyrwicz, MD",{"type":341,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100645523","phase-3-phase-3-study-of-cadonilimab-combined-with-chemotherapy-vs-chemotherapy-in-combination-with-or-without-nivolumab-for-the-1l-treatment-of-participants-with-her2-negative-previously-untreated-unresectable-or-metastatic-gastricgej-adenocarcinoma-100645523",false,"NCT07700979","Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric\u002FGEJ Adenocarcinoma","A Randomized, Double-blind, Multi-regional Phase 3 Study of Cadonilimab Combined With Chemotherapy Versus Chemotherapy in Combination With or Without Nivolumab for the First-line Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","G\u002FGEJ","Inclusion Criteria:\n\n1. Able to provide written informed consent and can understand and comply with the requirements of the study.\n2. Histopathologically-confirmed diagnosis of locally advanced unresectable or metastatic G\u002FGEJ adenocarcinoma.\n3. No prior systemic therapy for locally advanced unresectable or metastatic G\u002FGEJ adenocarcinoma. NOTE: For participants who have received prior neoadjuvant\u002Fadjuvant therapy for curative intent, the time between disease progression and last treatment should be at least 6 months.\n4. ECOG PS of 0 or 1 within 3 days prior to randomization.\n5. Age ≥ 18 years at the time of voluntarily signing informed consent.\n6. Evaluable PD-L1 expression results.\n7. Participants must have at least one measurable lesion per RECIST v1.1 as assessed by investigator assessment. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.\n8. Adequate organ function as indicated by the following laboratory values. Specimens must be collected within 7 days prior to the first dose of study treatment.\n9. Life expectancy ≥3 months.\n10. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to the first dose and agree to use effective contraception during treatment, and for at least 150 days after the last dose of cadonilimab\u002Fnivolumab, 270 days after the last dose of oxaliplatin, and 180 days after the last dose of capecitabine.\n11. Non-sterile males must agree to use effective contraception during treatment and for at least 120 days following the last dose of cadonilimab\u002Fnivolumab\u002Fcapecitabine and 180 days after the last dose of oxaliplatin.\n\nExclusion Criteria:\n\n1. Histopathologically confirmed other pathological types, such as squamous cell carcinoma, sarcoma or undifferentiated carcinoma.\n2. Known HER2 positive. Be HER2-positive defined as either IHC 3+ or IHC 2+ in combination with ISH+ (or FISH).\n3. Participants with active central nervous system (CNS) metastases and\u002For carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable (i.e., without evidence of progression) for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study intervention.\n4. Presence of clinically symptomatic pleural effusion, pericardial effusion, or ascites requiring frequent drainage (≥ 1 time\u002Fmonth).\n5. Clinically significant bleeding symptoms within 28 days before the first dose or a definite tendency to bleed.\n6. Have a history of ≥ Grade 2 gastrointestinal perforation and\u002For fistulae (including prior gastric fistula operation) within 6 months prior to randomization.\n7. Participants who, in the opinion of the investigator, have symptoms or signs suggestive of clinically unacceptable deterioration of the primary disease at the time of screening.","ALL","18 Years",{"count":353,"type":354},900,"ESTIMATED","INTERVENTIONAL",[357],"PHASE3","The goal of this randomized, double-blind, multi-regional phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy in combination with or without nivolumab for the first-line treatment of participants with HER2-negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma trial is to compare OS between cadonilimab combined with chemotherapy and chemotherapy in combination with or without nivolumab in the ITT population.",[360],"Gastric \u002F Gastroesophageal Junction Adenocarcinoma",[362,363,364,365,366,367,368],"Gastric\u002FGEJ adenocarcinoma","gastric cancer","cadonilimab","nivolumab","chemotherapy","HER2-negative cancer","Immunotherapy","NOT_YET_RECRUITING","2026-07-08",{"date":372,"type":373},"2026-07-14","ACTUAL",{"date":375,"type":354},"2026-08-20",{"date":377,"type":354},"2030-08-18",{"name":5,"class":6},25]